Metabolism and obesity are the focus of a major research initiative by the University of Gothenburg and AstraZeneca, with the ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

While this marks a significant acceleration of AstraZeneca's efforts, the deal with Absci isn't the pharma's first attempt at dabbling with AI for research and development (R&D) purposes.

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...

AstraZeneca reported fourth-quarter results ... the firm is making excellent strides with its research and development. Spending over 20% of sales on R&D with thoughtful investments, the firm ...

Novartis and Novo Nordisk — spent more on combined shareholder payments than on research and development. Five of the companies — J&J, Amgen, AstraZeneca, Novartis and Novo Nordisk — spent ...

In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare ...

LONDON (Reuters) - AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market ...

[Photo/China Daily] AstraZeneca, a United Kingdom-based biopharmaceutical giant, will add 10 to 15 new projects to the company's research and development pipeline in China each year, reflecting ...